Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV). [electronic resource]
Producer: 20181126Description: 1073-1076 p. digitalISSN:- 1473-5687
- 2-Naphthylamine
- Adult
- Aged
- Anilides -- adverse effects
- Antiviral Agents -- adverse effects
- Carbamates -- adverse effects
- Cyclopropanes
- Drug Combinations
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- complications
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis -- diagnosis
- Macrocyclic Compounds -- adverse effects
- Male
- Middle Aged
- Proline -- analogs & derivatives
- Republic of Belarus
- Ribavirin -- adverse effects
- Ritonavir -- adverse effects
- Russia
- Sulfonamides -- adverse effects
- Sustained Virologic Response
- Time Factors
- Treatment Outcome
- Uracil -- adverse effects
- Valine
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.